SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indevus Pharmaceuticals (NasdaqNM:IDEV) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (20)8/2/2004 1:48:02 PM
From: Sidney Street  Read Replies (2) | Respond to of 78
 
IDEV IR says that it can be assumed that on 12/1 IDEV will exercise its right to switch the arrangement to a royalty-based deal; the guidance being given is that it is a "mid-teens to mid-twenties" percent royalty, plus reimbursement for some of the cost of IDEV's specialty sales force selling into urology, ob/gyn, and high prescriber practices.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News